The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
London School of Hygiene & Tropical Medicine, London, UK.
Lancet. 2021 Nov 27;398(10315):1974-1983. doi: 10.1016/S0140-6736(21)02326-6. Epub 2021 Nov 15.
Contrast-associated acute kidney injury can occur after percutaneous coronary intervention (PCI). Prediction of the contrast-associated acute kidney injury risk is important for a tailored prevention and mitigation strategy. We sought to develop a simple risk score to estimate contrast-associated acute kidney injury risk based on a large contemporary PCI cohort.
Consecutive patients undergoing PCI at a large tertiary care centre between Jan 1, 2012, and Dec 31, 2020, with available creatinine measurements both before and within 48 h after the procedure, were included; only patients on chronic dialysis were excluded. Patients treated between 2012 and 2017 comprised the derivation cohort and those treated between 2018 and 2020 formed the validation cohort. The primary endpoint was contrast-associated acute kidney injury, defined according to the Acute Kidney Injury Network. Independent predictors of contrast-associated acute kidney injury were derived from multivariate logistic regression analysis. Model 1 included only pre-procedural variables, whereas Model 2 also included procedural variables. A weighted integer score based on the effect estimate of each independent variable was used to calculate the final risk score for each patient. The impact of contrast-associated acute kidney injury on 1-year deaths was also evaluated.
32 378 PCI procedures were performed and screened for inclusion in the present analysis. After the exclusion of patients without paired creatinine measurements, patients on chronic dialysis, and multiple procedures, 14 616 patients were included in the derivation cohort (mean age 66·2 years, 29·2% female) and 5606 were included in the validation cohort (mean age 67·0 years, 26·4% female). Contrast-associated acute kidney injury occurred in 860 (4·3%) patients. Independent predictors of contrast-associated acute kidney injury included in Model 1 were: clinical presentation, estimated glomerular filtration rate, left ventricular ejection fraction, diabetes, haemoglobin, basal glucose, congestive heart failure, and age. Additional independent predictors in Model 2 were: contrast volume, peri-procedural bleeding, no flow or slow flow post procedure, and complex PCI anatomy. The occurrence of contrast-associated acute kidney injury in the derivation cohort increased gradually from the lowest to the highest of the four risk score groups in both models (2·3% to 34·9% in Model 1, and 2·0% to 38·8% in Model 2). Inclusion of procedural variables in the model only slightly improved the discrimination of the risk score (C-statistic in the derivation cohort: 0·72 for Model 1 and 0·74 for model 2; in the validation cohort: 0·84 for Model 1 and 0·86 for Model 2). The risk of 1-year deaths significantly increased in patients with contrast-associated acute kidney injury (10·2% vs 2·5%; adjusted hazard ratio 1·76, 95% CI 1·31-2·36; p=0·0002), which was mainly due to excess 30-day deaths.
A contemporary simple risk score based on readily available variables from patients undergoing PCI can accurately discriminate the risk of contrast-associated acute kidney injury, the occurrence of which is strongly associated with subsequent death.
None.
经皮冠状动脉介入治疗(PCI)后可能会发生造影剂相关急性肾损伤。预测造影剂相关急性肾损伤的风险对于制定针对性的预防和缓解策略非常重要。我们旨在开发一种简单的风险评分,以根据大型当代 PCI 队列来估计造影剂相关急性肾损伤的风险。
纳入 2012 年 1 月 1 日至 2020 年 12 月 31 日期间在一家大型三级护理中心接受 PCI 的连续患者,在操作前后 48 小时内均有肌酐测量值;仅排除正在接受慢性透析的患者。2012 年至 2017 年治疗的患者构成推导队列,2018 年至 2020 年治疗的患者构成验证队列。主要终点是根据急性肾损伤网络定义的造影剂相关急性肾损伤。从多变量逻辑回归分析中得出造影剂相关急性肾损伤的独立预测因素。模型 1 仅包括术前变量,而模型 2 还包括手术变量。根据每个独立变量的效应估计值,使用加权整数评分来计算每个患者的最终风险评分。还评估了造影剂相关急性肾损伤对 1 年死亡率的影响。
共进行了 32378 次 PCI 手术,并筛选出符合纳入本分析的患者。排除无配对肌酐测量值、接受慢性透析和多次手术的患者后,14616 例患者被纳入推导队列(平均年龄 66.2 岁,29.2%为女性),5606 例患者被纳入验证队列(平均年龄 67.0 岁,26.4%为女性)。860 例(4.3%)患者发生造影剂相关急性肾损伤。模型 1 中造影剂相关急性肾损伤的独立预测因素包括:临床表现、估计肾小球滤过率、左心室射血分数、糖尿病、血红蛋白、基础血糖、充血性心力衰竭和年龄。模型 2 中的其他独立预测因素包括:造影剂用量、围手术期出血、术后无血流或血流缓慢以及复杂的 PCI 解剖结构。在推导队列中,根据两个模型,造影剂相关急性肾损伤的发生率在四个风险评分组中逐渐从最低到最高(模型 1 为 2.3%至 34.9%,模型 2 为 2.0%至 38.8%)。在模型中包含手术变量仅略微提高了风险评分的区分度(推导队列中的 C 统计量:模型 1 为 0.72,模型 2 为 0.74;验证队列:模型 1 为 0.84,模型 2 为 0.86)。发生造影剂相关急性肾损伤的患者 1 年死亡率显著增加(10.2%比 2.5%;调整后的危险比 1.76,95%CI 1.31-2.36;p=0.0002),这主要是由于 30 天内死亡人数增加。
基于接受 PCI 的患者可获得的现有变量,开发了一种当代简单风险评分,可以准确区分造影剂相关急性肾损伤的风险,而造影剂相关急性肾损伤与随后的死亡密切相关。
无。